Publication: The diverse signaling network of EGFR,
HER2, HER3 and HER4 tyrosine kinase receptors
and the consequences for therapeutic approaches
Authors
Zaczek, A. ; Brandt, B. ; Bielawski, K.P.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The HER family of receptor tyrosine kinase
couples binding of extracellular growth factor ligands to
intracellular signal transduction pathways, contributing
in this fashion to the ability of the cell to respond
correctly to its environment. The HER family and its
ligands are critically involved in the carcinogenesis of
the mammary gland. Abnormal function of the members
of HER family resulting in receptor hyper-activation
(due to gene amplification, protein overexpression or
abnormal transcriptional regulation) has been linked
with breast cancer prognosis. It is also extensively
studied as the predictive factor and target for therapy.
There are clinical indications supporting the concept that
none of the receptors: EGFR, HER2, HER3 and HER4
can be considered as the stand-alone receptor in breast
cancer development and clinical course of the disease.
There is a growing body of evidence that cooperation
between them contributes to more aggressive tumor
phenotype and influences the response to therapy. This
underlines the importance of quantification of all HER
family members and indicates the urgent need for
implementation of methods that can efficiently and
reliably examine four HER receptors as a whole panel in
breast cancer patients.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.